Report on the clinical evaluation of glutaraldehyde cross-linked collagen (Keragen implant) for the treatment of tylomas. Collagen Podiatric Investigation Group.
Glutaraldehyde cross-linked collagen, Keragen implant, was injected subdermally beneath tylomas for the relief of both the pain and keratoses associated with these lesions. Among 130 patients, 205 tylomas were treated with Keragen implant, while 185 tylomas served as uninjected control sites, which were treated only with palliative care. Most lesions (93%) required only 1 treatment; and the mean total volume implanted with 1.78 ml./lesion. The intensity and frequency of pain were lower among implanted lesions than among control sites up to 12 months following treatment. Furthermore, at 9 to 12 months following treatment, the extent of the keratotic lesions were reduced more frequently among the implanted lesions (45%) than among the control sites (27%); more nucleated lesions became non-nucleated for up to 12 months following treatment in the implanted group (61%) than in the control group (45%). Thus, these results indicate that subdermal injection of Keragen implant collagen can provide significant retardation in the formation of keratosis and reduction in the pain associated with tylomas.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002145:Callosities / Q000628:therapy*; D002986:Clinical Trials as Topic; D003094:Collagen; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019736:Prostheses and Implants
C048470:glutaraldehyde-cross-linked collagen; D003094:Collagen